


Correction

# Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. *J. Clin. Med.* 2022, 11, 5828

Shun Kohsaka <sup>1</sup> , Suguru Okami <sup>2</sup>, Naru Morita <sup>2</sup> and Toshitaka Yajima <sup>2,\*</sup>


<sup>1</sup> Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan

<sup>2</sup> Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka 530-0011, Japan

\* Correspondence: toshitaka.yajima@astrazeneca.com; Tel.: +81-6-4802-3600; Fax: +81-3-3457-9301

## Error in Figure

In the original publication [1], there was a mistake in Figure 3 as published. Some prescription numbers and percentages in ACEi, ARB and MRA were wrong. The corrected Figure 3 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.



**Figure 3.** RAASi treatment according to dosage category (high, medium, or low) at the index date. Percentages were calculated using the total number of prescriptions. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; RAASi, renin–angiotensin–aldosterone system inhibitor.

## Reference

1. Kohsaka, S.; Okami, S.; Morita, N.; Yajima, T. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. *J. Clin. Med.* **2022**, *11*, 5828. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



**Citation:** Kohsaka, S.; Okami, S.; Morita, N.; Yajima, T. Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. *J. Clin. Med.* **2022**, *11*, 5828. *J. Clin. Med.* **2023**, *12*, 2578. <https://doi.org/10.3390/jcm12072578>

Received: 16 March 2023

Accepted: 20 March 2023

Published: 29 March 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).